Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial

Table 1 Overview of DMARDs in psoriatic arthritis, radiographic axial spondyloarthritis and non-radiographic axial spondyloarthritis

	Psoriatic arthritis	Radiographic axial spondyloartritis	Non-radiographic axial spondyloarthritis
bDMARDs
TNFi	Adalimumab 40 mg 1x/2 weeks Certolizumab 200 mg 1x/2 weeks Etanercept 25 mg 2x/week or 50 mg 1x/week Golimumab 50 mg 1x/month Infliximab *5 mg/kg 1x/8 weeks	Adalimumab 40 mg 1x/2 weeks Certolizumab 200 mg 1x/2 weeks Etanercept 25 mg 2x/week or 50 mg 1x/week Golimumab 50 mg 1x/month Infliximab *5 mg/kg 1x/8 weeks	Adalimumab 40 mg 1x/2 weeks Certolizumab 200 mg 1x/2 weeks Etanercept 25 mg 2x/week or 50 mg 1x/week Golimumab 50 mg 1x/month
Anti-IL-17	Secukinumab 150 mg 1x/month (up to 300 mg) Ixekizumab 80 mg 1x/4 weeks	Secukinumab *150 mg 1x/month
Anti-IL-23, IL-12	Ustekinumab *45 mg 1x/12 weeks
CTLA4-Ig	Abatacept *125 mg 1x/week
PDE-4i	Apremilast *30 mg 2x/day
JAKi	Tofacitinib *5 mg 2x/day

DMARD disease-modifying anti-rheumatic drug, bDMARD biological DMARD, TNFi tumour necrosis factor inhibitor, IL interleukin, CTLA4-Ig cytotoxic T-lymphocyte associated protein 4-immunoglobulin, PDE-4i phosphodiesterase-4 inhibitor, JAKi janus kinase inhibitor
*Registered dosage in psoriatic arthritis, axial spondyloarthritis and non-radiographic axial spondyloarthritis

ISSN: 1745-6215